Latest:
Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions
Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ritu Salani, MD
Ritu Salani, MD, MBA, is a board-certified gynecologic oncologist who is a nationally renowned expert in the treatment of gynecologic malignancies with over 15 years of experience. She serves as the Director of Gynecologic Oncology at UCLA.
Latest:
Navigating T-DXd-Related Toxicity: Mitigation and Management Strategies in Gynecological Cancer
Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.
Robb S. Friedman, MD
Latest:
Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma
Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.
Robert A. Figlin, MD, FACP
Latest:
Dr. Figlin on Treatment Strategies in Advanced RCC
Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses treatment strategies for patients with advanced renal cell carcinoma.
Robert A. Wolff, MD
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Robert Andtbacka, MD
Latest:
Dr. Andtbacka Discusses Next Steps With T-VEC in Melanoma
Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.